Ascendis Pharma registers Phase 3 trial of Yorvipath in adolescent hypoparathyroidism
A new registry record shows a Phase 3 study testing palopegteriparatide in adolescents with chronic hypoparathyroidism, recruiting at sites in France and Poland.
Ascendis Pharma A/S has a new trial record listed on ClinicalTrials.gov, first posted 2026-07-16.
- The study, NCT07706764, is a Phase 3, single-arm trial of palopegteriparatide (also known as Yorvipath) in adolescents aged 12 to under 18 with chronic hypoparathyroidism. The trial will enroll adolescents between ages of ≥12 and <18 years with clinically diagnosed hypoparathyroidism.1 The record lists the study status as recruiting, with an actual start date of 2026-04-22. At least 12 participants will receive palopegteriparatide for 234 weeks.1 The primary outcome is a multicomponent efficacy measure assessed at Week 26. This endpoint tracks the percentage of participants who have albumin-adjusted serum calcium within the normal range, independence from active vitamin D, and independence from therapeutic doses of calcium.1 The trial will be conducted in Europe,1 with sites listed in France and Poland.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.